Jelmer Raaijmakers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jelmer Raaijmakers has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Jakko van Ingen
Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands
7 shared publications - Jodie Anne Schildkraut
Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, Netherlands
3 shared publications - Ralf Stemkens
Department of Pharmacy, Pharmacology & Toxicology, Radboudumc Community for Infectious Diseases, Radboud University Medical Center , Nijmegen
3 shared publications Wouter Hoefsloot
Radboudumc Community for Infectious Diseases, Research Institute for Medical Innovation, Department of Pulmonary Diseases, Radboud University Medical Center , Nijmegen 6500 HB
3 shared publications- Elin M. Svensson
Department of Pharmacy Uppsala University Uppsala Sweden
2 shared publications Lindsey Te Brake
Radboudumc Community for Infectious Diseases, Research Institute for Medical Innovation, Department of Pharmacy, Radboud University Medical Center , Nijmegen
2 shared publications
Latest Publications
- Open Access
- 10 November 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (1)
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
Background and objectives: Treatment outcomes in Mycobacterium avium complex pulmonary disease may be improved by adding clofazimine, instead of rifampicin, to the azithromycin-ethambutol backbone. Inhalation of clofazimine instead of oral administration has been suggested to increase the antibiotic concentration at the site of infection and to improve its efficacy, while minimizing systemic exposure and adverse effects. We evaluated the efficacy of inhaled clofazimine compared to oral clofazimine with an azithromycin-ethambutol backbone against M. avium. Methods: We simulated pharmacokinetic exposures to azithromycin, ethambutol and either inhalational or oral clofazimine administration in an in vitro hollow-fiber system during 3 weeks. Intracellular and extracellular Mycobacterium avium ATCC 700898 bacteria were exposed to these antibiotic regimens and bacterial densities were enumerated at day 0, 3, 7, 14 and 21. The development of macrolide resistance was assessed by inoculation of agar plates containing azithromycin. Pharmacokinetic exposures were confirmed on day 0 and 21. Results: Inhalational administration of clofazimine significantly increased the antimycobacterial effect of the regimen against both intracellular and extracellular bacteria. The inhaled treatment showed an intracellular kill rate of 0.62 (95%C.I. 0.61–0.64) per day, while the oral administration showed a kill rate of 0.55 (95%C.I. 0.54–0.56) per day. For the extracellular fraction, inhaled administration showed a kill rate of 0.56 (95%C.I. 0.55–0.58) per day and the oral administration a kill rate of 0.50 (95%C.I. 0.50–0.51) per day. Inhaled clofazimine exposures reduced and delayed the emergence of macrolide resistance. Conclusions: Inhalation of clofazimine with an azithromycin-ethambutol backbone increases treatment efficacy and decreases the development of macrolide resistance compared to oral administration in a hollow-fiber system. This calls for a clinical trial of inhaled clofazimine.
- 10 November 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (1)
Open AccessEnhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
Background and objectives: Treatment outcomes in Mycobacterium avium complex pulmonary disease may be improved by adding clofazimine, instead of rifampicin, to the azithromycin-ethambutol backbone. Inhalation of clofazimine instead of oral administration has been suggested to increase the antibiotic concentration at the site of infection and to improve its efficacy, while minimizing systemic exposure and adverse effects. We evaluated the efficacy of inhaled clofazimine compared to oral clofazimine with an azithromycin-ethambutol backbone against M. avium. Methods: We simulated pharmacokinetic exposures to azithromycin, ethambutol and either inhalational or oral clofazimine administration in an in vitro hollow-fiber system during 3 weeks. Intracellular and extracellular Mycobacterium avium ATCC 700898 bacteria were exposed to these antibiotic regimens and bacterial densities were enumerated at day 0, 3, 7, 14 and 21. The development of macrolide resistance was assessed by inoculation of agar plates containing azithromycin. Pharmacokinetic exposures were confirmed on day 0 and 21. Results: Inhalational administration of clofazimine significantly increased the antimycobacterial effect of the regimen against both intracellular and extracellular bacteria. The inhaled treatment showed an intracellular kill rate of 0.62 (95%C.I. 0.61–0.64) per day, while the oral administration showed a kill rate of 0.55 (95%C.I. 0.54–0.56) per day. For the extracellular fraction, inhaled administration showed a kill rate of 0.56 (95%C.I. 0.55–0.58) per day and the oral administration a kill rate of 0.50 (95%C.I. 0.50–0.51) per day. Inhaled clofazimine exposures reduced and delayed the emergence of macrolide resistance. Conclusions: Inhalation of clofazimine with an azithromycin-ethambutol backbone increases treatment efficacy and decreases the development of macrolide resistance compared to oral administration in a hollow-fiber system. This calls for a clinical trial of inhaled clofazimine.
- Open Access
- 30 October 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (10) , 002072
A viable but nonculturable state of Mycobacterium avium in response to macrolide antibiotics: a recipe for relapses?
Mycobacterium avium complex disease is difficult to treat, with high failure and recurrence rates despite multidrug, macrolide-based treatments. The bacterial mechanisms involved in this drug tolerance and persistence are incompletely understood. Recent evidence has suggested persistence through metabolic adaptations indicative of the viable but nonculturable state, including a decreased respiratory rate and a switch to lipid accumulation and metabolism. To assess the contribution of switching to viable but nonculturable state to macrolide tolerance, we performed time–kill kinetics assays for clarithromycin against M. avium . In these experiments, we performed Auramine-O (for acid-fastness, representing active mycobacteria) and Nile red (for lipid accumulation) staining and stimulation using resuscitation-promoting factors of Mycobacterium tuberculosis . Loss of auramine staining, increased Nile red staining and increased population sizes after stimulation with resuscitation-promoting factors support the hypothesis that clarithromycin induces a viable but nonculturable state in M. avium . Induction of a viable but nonculturable state is one of the mechanisms of macrolide tolerance in M. avium . It might be one of the drivers of the high failure and recurrence rates of macrolide-based treatments. Antimicrobials active against viable but nonculturable M. avium may improve treatment outcomes.
- 30 October 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (10) , 002072
Open AccessA viable but nonculturable state of Mycobacterium avium in response to macrolide antibiotics: a recipe for relapses?
Mycobacterium avium complex disease is difficult to treat, with high failure and recurrence rates despite multidrug, macrolide-based treatments. The bacterial mechanisms involved in this drug tolerance and persistence are incompletely understood. Recent evidence has suggested persistence through metabolic adaptations indicative of the viable but nonculturable state, including a decreased respiratory rate and a switch to lipid accumulation and metabolism. To assess the contribution of switching to viable but nonculturable state to macrolide tolerance, we performed time–kill kinetics assays for clarithromycin against M. avium . In these experiments, we performed Auramine-O (for acid-fastness, representing active mycobacteria) and Nile red (for lipid accumulation) staining and stimulation using resuscitation-promoting factors of Mycobacterium tuberculosis . Loss of auramine staining, increased Nile red staining and increased population sizes after stimulation with resuscitation-promoting factors support the hypothesis that clarithromycin induces a viable but nonculturable state in M. avium . Induction of a viable but nonculturable state is one of the mechanisms of macrolide tolerance in M. avium . It might be one of the drivers of the high failure and recurrence rates of macrolide-based treatments. Antimicrobials active against viable but nonculturable M. avium may improve treatment outcomes.
- Open Access
- 7 May 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (5) , e0146424
Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system
Bedaquiline has been proposed as a second-line drug to treat pulmonary disease caused by Mycobacterium avium complex. Based on in vitro synergy and interactions, a logical regimen would combine bedaquiline and clofazimine as additions to an ethambutol-azithromycin backbone. Here, we evaluate the added benefit of bedaquiline in a regimen of azithromycin, ethambutol, and clofazimine. THP-1 cells infected with M. avium ATCC 700898 were seeded in a hollow-fiber model and exposed to a regimen of azithromycin, ethambutol, and clofazimine with or without bedaquiline for 3 weeks. Epithelial lining fluid pharmacokinetic profiles of azithromycin and ethambutol were simulated, while an average steady-state concentration was sought for clofazimine and bedaquiline. Pharmacokinetics and pharmacodynamics were monitored throughout the experiment. Both regimens led to sustained bacterial killing (both intracellular and extracellular) throughout the experiment. No difference in kill rate was observed between the two therapies. The extracellular kill rate for the 3-drug regimen was 0.65 (95% CI 0.63–0.67) and for the 4-drug regimen 0.65 (95% CI 0.64–0.67). The intracellular kill rate was 0.48 (95% CI 0.46–0.50) for the 3-drug regimen and 0.48 (95% CI 0.46–0.50) for the 4-drug regimen. Macrolide-tolerant subpopulations were observed with both treatment regimens at day 21. Bedaquiline does not add killing activity to a clofazimine-ethambutol-azithromycin regimen and did not improve suppression of the emergence of macrolide resistance, which makes its role as a second-line agent doubtful.
- 7 May 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (5) , e0146424
Open AccessBedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system
Bedaquiline has been proposed as a second-line drug to treat pulmonary disease caused by Mycobacterium avium complex. Based on in vitro synergy and interactions, a logical regimen would combine bedaquiline and clofazimine as additions to an ethambutol-azithromycin backbone. Here, we evaluate the added benefit of bedaquiline in a regimen of azithromycin, ethambutol, and clofazimine. THP-1 cells infected with M. avium ATCC 700898 were seeded in a hollow-fiber model and exposed to a regimen of azithromycin, ethambutol, and clofazimine with or without bedaquiline for 3 weeks. Epithelial lining fluid pharmacokinetic profiles of azithromycin and ethambutol were simulated, while an average steady-state concentration was sought for clofazimine and bedaquiline. Pharmacokinetics and pharmacodynamics were monitored throughout the experiment. Both regimens led to sustained bacterial killing (both intracellular and extracellular) throughout the experiment. No difference in kill rate was observed between the two therapies. The extracellular kill rate for the 3-drug regimen was 0.65 (95% CI 0.63–0.67) and for the 4-drug regimen 0.65 (95% CI 0.64–0.67). The intracellular kill rate was 0.48 (95% CI 0.46–0.50) for the 3-drug regimen and 0.48 (95% CI 0.46–0.50) for the 4-drug regimen. Macrolide-tolerant subpopulations were observed with both treatment regimens at day 21. Bedaquiline does not add killing activity to a clofazimine-ethambutol-azithromycin regimen and did not improve suppression of the emergence of macrolide resistance, which makes its role as a second-line agent doubtful.
- Open Access
- 27 December 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 65 (2) , 107423
Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system
- 27 December 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 65 (2) , 107423
Open AccessReplacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system
- Open Access
- 6 March 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (3) , e0115723
Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model
Mycobacterium avium complex pulmonary disease is treated with an azithromycin, ethambutol, and rifampicin regimen, with limited efficacy. The role of rifampicin is controversial due to inactivity, adverse effects, and drug interactions. Here, we evaluated the efficacy of clofazimine as a substitute for rifampicin in an intracellular hollow-fiber infection model. THP-1 cells, which are monocytes isolated from peripheral blood from an acute monocytic leukemia patient, were infected with M. avium ATCC 700898 and exposed to a regimen of azithromycin and ethambutol with either rifampicin or clofazimine. Intrapulmonary pharmacokinetic profiles of azithromycin, ethambutol, and rifampicin were simulated. For clofazimine, a steady-state average concentration was targeted. Drug concentrations and bacterial densities were monitored over 21 days. Exposures to azithromycin and ethambutol were 20%–40% lower than targeted but within clinically observed ranges. Clofazimine exposures were 1.7 times higher than targeted. Until day 7, both regimens were able to maintain stasis. Thereafter, regrowth was observed for the rifampicin-containing regimen, while the clofazimine-containing regimen yielded a 2 Log 10 colony forming unit (CFU) per mL decrease in bacterial load. The clofazimine regimen also successfully suppressed the emergence of macrolide tolerance. In summary, substitution of rifampicin with clofazimine in the hollow-fiber model improved the antimycobacterial activity of the regimen. Clofazimine-containing regimens merit investigation in clinical trials.
- 6 March 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (3) , e0115723
Open AccessClofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model
Mycobacterium avium complex pulmonary disease is treated with an azithromycin, ethambutol, and rifampicin regimen, with limited efficacy. The role of rifampicin is controversial due to inactivity, adverse effects, and drug interactions. Here, we evaluated the efficacy of clofazimine as a substitute for rifampicin in an intracellular hollow-fiber infection model. THP-1 cells, which are monocytes isolated from peripheral blood from an acute monocytic leukemia patient, were infected with M. avium ATCC 700898 and exposed to a regimen of azithromycin and ethambutol with either rifampicin or clofazimine. Intrapulmonary pharmacokinetic profiles of azithromycin, ethambutol, and rifampicin were simulated. For clofazimine, a steady-state average concentration was targeted. Drug concentrations and bacterial densities were monitored over 21 days. Exposures to azithromycin and ethambutol were 20%–40% lower than targeted but within clinically observed ranges. Clofazimine exposures were 1.7 times higher than targeted. Until day 7, both regimens were able to maintain stasis. Thereafter, regrowth was observed for the rifampicin-containing regimen, while the clofazimine-containing regimen yielded a 2 Log 10 colony forming unit (CFU) per mL decrease in bacterial load. The clofazimine regimen also successfully suppressed the emergence of macrolide tolerance. In summary, substitution of rifampicin with clofazimine in the hollow-fiber model improved the antimycobacterial activity of the regimen. Clofazimine-containing regimens merit investigation in clinical trials.
- Open Access
- 15 November 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (11) , e0087423
The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
Rifampicin is recommended for the treatment of Mycobacterium avium complex pulmonary disease alongside azithromycin and ethambutol. We evaluated the azithromycin-ethambutol backbone with and without rifampicin in an intracellular hollow fiber model and performed RNA sequencing to study the differences in adaptation. In an in vitro hollow fiber experiment, we simulated epithelial lining fluid pharmacokinetic profiles of the recommended 3-drug (rifampicin, ethambutol, and azithromycin) or a 2-drug (ethambutol and azithromycin) treatment. THP-1 cells infected with M. avium ATCC700898 were exposed to these regimens for 21 days. We determined intra- and extra-cellular bacterial load- and THP-1 cell densities on days 0, 3, 7, 14, and 21, alongside RNA sequencing. The emergence of macrolide resistance was studied by inoculating intra- and extra-cellular fractions of azithromycin-containing Middlebrook 7H10 agar plates. Complete pharmacokinetic profiles were determined at days 0 and 21. Both therapies maintained stasis of both intra- and extra-cellular bacterial populations for 3 days, whilst regrowth coinciding with the emergence of a macrolide-resistant subpopulation was seen after 7 days. THP-1 cell density remained static. Similar transcriptional profiles were observed for both therapies that were minimally influenced by exposure duration. Transcriptional response was slightly larger during 2-drug treatment. Rifampicin did not add to the antimycobacterial effect to the 2-drug therapy or suppression of emergence resistance. RNA transcription was not greatly altered by the addition of rifampicin, which may be due to strong transcriptional influence of azithromycin and host cells. This questions the role of rifampicin in the currently recommended therapy. These findings should be confirmed in clinical trials.
- 15 November 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (11) , e0087423
Open AccessThe role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
Rifampicin is recommended for the treatment of Mycobacterium avium complex pulmonary disease alongside azithromycin and ethambutol. We evaluated the azithromycin-ethambutol backbone with and without rifampicin in an intracellular hollow fiber model and performed RNA sequencing to study the differences in adaptation. In an in vitro hollow fiber experiment, we simulated epithelial lining fluid pharmacokinetic profiles of the recommended 3-drug (rifampicin, ethambutol, and azithromycin) or a 2-drug (ethambutol and azithromycin) treatment. THP-1 cells infected with M. avium ATCC700898 were exposed to these regimens for 21 days. We determined intra- and extra-cellular bacterial load- and THP-1 cell densities on days 0, 3, 7, 14, and 21, alongside RNA sequencing. The emergence of macrolide resistance was studied by inoculating intra- and extra-cellular fractions of azithromycin-containing Middlebrook 7H10 agar plates. Complete pharmacokinetic profiles were determined at days 0 and 21. Both therapies maintained stasis of both intra- and extra-cellular bacterial populations for 3 days, whilst regrowth coinciding with the emergence of a macrolide-resistant subpopulation was seen after 7 days. THP-1 cell density remained static. Similar transcriptional profiles were observed for both therapies that were minimally influenced by exposure duration. Transcriptional response was slightly larger during 2-drug treatment. Rifampicin did not add to the antimycobacterial effect to the 2-drug therapy or suppression of emergence resistance. RNA transcription was not greatly altered by the addition of rifampicin, which may be due to strong transcriptional influence of azithromycin and host cells. This questions the role of rifampicin in the currently recommended therapy. These findings should be confirmed in clinical trials.
- Open Access
- 26 September 2023
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 78 (11) , 2723-2730
Development and validation of a bioanalytical assay for the measurement of total and unbound teicoplanin in human serum
Background: The glycopeptide teicoplanin is considered first-line treatment for severe infections caused by Gram-positive bacteria. Individualized treatment of teicoplanin is gaining interest. As only protein-unbound drug is pharmacologically active, a sensitive assay measuring unbound and total teicoplanin is indispensable for pharmacological research and dose optimization. Objectives: To develop and validate a UPLC-MS/MS method to quantify unbound and total teicoplanin in human serum. Methods: The developed assay was validated according to the ICH guideline M10 on Bioanalytical Method Validation and study sample analysis. Unbound teicoplanin was obtained by ultrafiltration. The assay was cross-validated with a quantitative microsphere (QMS) immunoassay in a side-by-side comparison using 40 patient samples. Results: With the developed and validated method, all main teicoplanin components (A2-1, A2-2/A2-3, A2-4/A2-5 and A3-1) can be quantified. Total run time was 5.5 min. Concentration range was 2.5–150 mg/L for total and 0.1–25 mg/L for unbound teicoplanin. Precision (coefficient of variation) and accuracy (bias) of total teicoplanin were 5.97% and 107%, respectively, and 7.17% and 108%, respectively, for unbound teicoplanin. Bland–Altman analysis showed total concentrations measured with the UPLC-MS/MS method were equivalent to the results of the QMS immunoassay. A total of 188 samples from 30 patients admitted to the ICU and haematology department were measured; total concentrations ranged between 2.92 and 98.5 mg/L, and unbound concentrations ranged between 0.37 and 30.7 mg/L. Conclusions: The developed method provided rapid, precise and accurate measurement of unbound and total teicoplanin. The developed method is now routinely applied in pharmacological research and clinical practice.
- 26 September 2023
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 78 (11) , 2723-2730
Open AccessDevelopment and validation of a bioanalytical assay for the measurement of total and unbound teicoplanin in human serum
Background: The glycopeptide teicoplanin is considered first-line treatment for severe infections caused by Gram-positive bacteria. Individualized treatment of teicoplanin is gaining interest. As only protein-unbound drug is pharmacologically active, a sensitive assay measuring unbound and total teicoplanin is indispensable for pharmacological research and dose optimization. Objectives: To develop and validate a UPLC-MS/MS method to quantify unbound and total teicoplanin in human serum. Methods: The developed assay was validated according to the ICH guideline M10 on Bioanalytical Method Validation and study sample analysis. Unbound teicoplanin was obtained by ultrafiltration. The assay was cross-validated with a quantitative microsphere (QMS) immunoassay in a side-by-side comparison using 40 patient samples. Results: With the developed and validated method, all main teicoplanin components (A2-1, A2-2/A2-3, A2-4/A2-5 and A3-1) can be quantified. Total run time was 5.5 min. Concentration range was 2.5–150 mg/L for total and 0.1–25 mg/L for unbound teicoplanin. Precision (coefficient of variation) and accuracy (bias) of total teicoplanin were 5.97% and 107%, respectively, and 7.17% and 108%, respectively, for unbound teicoplanin. Bland–Altman analysis showed total concentrations measured with the UPLC-MS/MS method were equivalent to the results of the QMS immunoassay. A total of 188 samples from 30 patients admitted to the ICU and haematology department were measured; total concentrations ranged between 2.92 and 98.5 mg/L, and unbound concentrations ranged between 0.37 and 30.7 mg/L. Conclusions: The developed method provided rapid, precise and accurate measurement of unbound and total teicoplanin. The developed method is now routinely applied in pharmacological research and clinical practice.
- Open Access
- 22 July 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (15) , 1961-1974
The role of amikacin in the treatment of nontuberculous mycobacterial disease
Introduction: Guidelines recommend the use of amikacin in the treatment of nontuberculous mycobacterial (NTM) disease. The authors have evaluated the evidence for the position of amikacin in NTM disease treatment. Areas covered: The authors performed a literature search for original research on amikacin in NTM disease, including its mechanism of action, emergence of resistance, pre-clinical and clinical investigations. Expert opinion: Amikacin shows moderate in vitro activity against the clinically most relevant NTM species (M. avium complex and M. abscessus). It is synergistic with ethambutol, clofazimine, and macrolides and these combinations are effective in animal models. Liposomal encapsulation increases amikacin efficacy. Clinically, the recommended dose of 15 mg/kg intravenous amikacin does not lead to PK/PD target attainment in all patients and a positive impact on long-term treatment outcomes remains unproven in both M. avium complex and M. abscessus disease. Adding the amikacin liposome inhalation suspension did prove to be effective in short and long term in patients not responding to recommended treatment for M. avium complex pulmonary disease. Its optimal use in M. avium complex and M. abscessus pulmonary disease warrants further evaluation.
- 22 July 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (15) , 1961-1974
Open AccessThe role of amikacin in the treatment of nontuberculous mycobacterial disease
Introduction: Guidelines recommend the use of amikacin in the treatment of nontuberculous mycobacterial (NTM) disease. The authors have evaluated the evidence for the position of amikacin in NTM disease treatment. Areas covered: The authors performed a literature search for original research on amikacin in NTM disease, including its mechanism of action, emergence of resistance, pre-clinical and clinical investigations. Expert opinion: Amikacin shows moderate in vitro activity against the clinically most relevant NTM species (M. avium complex and M. abscessus). It is synergistic with ethambutol, clofazimine, and macrolides and these combinations are effective in animal models. Liposomal encapsulation increases amikacin efficacy. Clinically, the recommended dose of 15 mg/kg intravenous amikacin does not lead to PK/PD target attainment in all patients and a positive impact on long-term treatment outcomes remains unproven in both M. avium complex and M. abscessus disease. Adding the amikacin liposome inhalation suspension did prove to be effective in short and long term in patients not responding to recommended treatment for M. avium complex pulmonary disease. Its optimal use in M. avium complex and M. abscessus pulmonary disease warrants further evaluation.